ArticleVirchows Archiv : an international journal of pathology2026
POLE-mutated endometrial carcinoma with extreme morphological and molecular heterogeneity: spatial clonal divergence in a multiple-classifier tumor.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POLE-mutated endometrial carcinomas are typically associated with favorable prognosis, yet marked spatial heterogeneity may complicate biological and clinical interpretation. We report a unique triphasic carcinoma composed of endometrioid, dedifferentiated-like, and sarcomatoid-like components with distinct morphologic and immunophenotypic profiles. Multiregional sequencing demonstrated a shared pathogenic POLE V411L mutation across all components, confirming a common clonal origin. Progressive molecular divergence was observed, with subclonal MSH6 alteration in the endometrioid region, complete MSH6 loss and dramatic tumor mutational burden escalation in the dedifferentiated-like and sarcomatoid-like components, and acquisition of TP53 and ARID1A truncating mutations restricted to the sarcomatoid-like compartment. Despite high-grade transformation and stage IIC disease, microsatellite stability was maintained, supporting a POLE-driven hypermutator phenotype. This case provides direct morphologic and molecular evidence of spatial clonal evolution in a multiple-classifier endometrial carcinoma. The clinical implications of this spatial heterogeneity remain uncertain and warrant further investigation.
Indexed as
Identifiers
41949782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.